MeSH term
Frequency | Condition_Probility | Complement 4a/*genetics | 27 | 77.0 |
Complement 4b/*genetics | 29 | 85.0 |
*Gene Conversion | 4 | 12.0 |
Haplotypes | 54 | 2.0 |
Humans | 400 | 0.0 |
Introns | 2 | 0.0 |
Major Histocompatibility Complex | 22 | 9.0 |
Research Support, Non-U.S. Gov't | 268 | 0.0 |
Adolescent | 56 | 0.0 |
Adult | 84 | 0.0 |
Aged | 33 | 0.0 |
Aged, 80 and over | 10 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Case-Control Studies | 8 | 0.0 |
Complement 3/*immunology | 3 | 4.0 |
Complement 4/*immunology | 5 | 26.0 |
Complement Pathway, Classical | 5 | 4.0 |
Electrophoresis, Agar Gel | 9 | 1.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Female | 145 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Male | 136 | 0.0 |
Middle Aged | 59 | 0.0 |
Alleles | 94 | 1.0 |
Complement 3/*genetics | 6 | 10.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Genotype | 34 | 0.0 |
HLA-B Antigens/*genetics | 3 | 1.0 |
Phenotype | 64 | 0.0 |
English Abstract | 11 | 0.0 |
Gene Expression | 5 | 0.0 |
Gene Frequency | 62 | 1.0 |
Genetic Markers | 14 | 0.0 |
HLA Antigens/*genetics | 37 | 4.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Autistic Disorder/*genetics | 2 | 3.0 |
Complement 4/*genetics | 67 | 48.0 |
Gene Deletion | 13 | 0.0 |
*Major Histocompatibility Complex | 28 | 9.0 |
Research Support, U.S. Gov't, P.H.S. | 112 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 4 | 1.0 |
Amino Acid Sequence | 31 | 0.0 |
Animals | 46 | 0.0 |
Autoimmune Diseases/genetics | 2 | 7.0 |
Complement/genetics | 9 | 33.0 |
Molecular Sequence Data | 46 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Terminology | 3 | 2.0 |
Variation (Genetics) | 13 | 0.0 |
Child | 45 | 0.0 |
Child, Preschool | 27 | 0.0 |
Complement 4a/*deficiency | 3 | 75.0 |
Complement 4b/*deficiency | 7 | 100.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Infant | 16 | 0.0 |
Base Sequence | 36 | 0.0 |
Comparative Study | 54 | 0.0 |
DNA/genetics | 10 | 0.0 |
Mice | 15 | 0.0 |
Molecular Structure | 2 | 0.0 |
Polymorphism, Genetic | 45 | 1.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Species Specificity | 5 | 0.0 |
*Alleles | 26 | 1.0 |
DNA/analysis | 9 | 1.0 |
DNA Primers | 3 | 0.0 |
Polymerase Chain Reaction/*methods | 4 | 0.0 |
*Polymorphism, Genetic | 29 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Attention Deficit Disorder with Hyperactivity/*genetics | 2 | 4.0 |
Chi-Square Distribution | 2 | 0.0 |
Genetic Screening | 2 | 0.0 |
*Linkage (Genetics) | 7 | 0.0 |
Nuclear Family | 2 | 0.0 |
HLA-A Antigens | 4 | 1.0 |
*Mutation | 3 | 0.0 |
Polymerase Chain Reaction | 12 | 0.0 |
Polymorphism, Restriction Fragment Length | 31 | 1.0 |
Antibodies/blood/*immunology | 2 | 20.0 |
Follow-Up Studies | 3 | 0.0 |
Logistic Models | 3 | 0.0 |
Complement 2/genetics | 10 | 20.0 |
Complement Pathway, Classical/genetics | 3 | 42.0 |
HLA-DR Antigens/genetics | 11 | 2.0 |
Exons | 5 | 0.0 |
HLA-DQ Antigens/genetics | 4 | 1.0 |
Hepatitis B Vaccines/*immunology | 2 | 15.0 |
Complement 4b/genetics | 13 | 61.0 |
Endogenous Retroviruses/genetics | 2 | 40.0 |
Haplotypes/genetics | 6 | 1.0 |
Steroid 21-Hydroxylase/genetics | 13 | 30.0 |
Blotting, Western | 5 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Ethnic Groups/*genetics | 3 | 1.0 |
European Continental Ancestry Group/genetics | 6 | 0.0 |
Reference Values | 8 | 0.0 |
Sampling Studies | 2 | 1.0 |
*Variation (Genetics) | 8 | 0.0 |
Adrenal Hyperplasia, Congenital/genetics | 3 | 27.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Gene Conversion | 5 | 8.0 |
Gene Dosage | 3 | 0.0 |
Heterozygote | 8 | 0.0 |
Major Histocompatibility Complex/genetics | 3 | 5.0 |
Mutation | 7 | 0.0 |
Steroid 21-Hydroxylase/*genetics | 25 | 39.0 |
Tenascin/*genetics | 2 | 14.0 |
Chromosome Mapping | 33 | 0.0 |
Family | 3 | 0.0 |
*Linkage Disequilibrium | 2 | 1.0 |
Major Histocompatibility Complex/*genetics | 14 | 8.0 |
Antigen-Antibody Complex/*blood | 4 | 7.0 |
Complement 4/deficiency/*genetics | 9 | 64.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Transfection | 6 | 0.0 |
Antigen-Antibody Complex/metabolism | 4 | 7.0 |
Complement/metabolism | 2 | 2.0 |
Complement 1/metabolism | 3 | 7.0 |
Complement 1q/*metabolism | 2 | 10.0 |
Complement 4b/*metabolism | 7 | 38.0 |
Kinetics | 9 | 0.0 |
Protein Binding/immunology | 2 | 1.0 |
Receptors, Complement 3b/immunology/*metabolism | 2 | 50.0 |
*Gene Deletion | 4 | 0.0 |
Homozygote | 13 | 0.0 |
Recurrence | 4 | 0.0 |
Binding, Competitive | 4 | 0.0 |
Cattle | 4 | 0.0 |
Complement 4a/*metabolism | 2 | 100.0 |
Serum Albumin, Bovine/immunology | 2 | 8.0 |
Blotting, Southern | 13 | 0.0 |
Brazil | 3 | 1.0 |
Cohort Studies | 2 | 0.0 |
Complement 3/analysis/*genetics | 2 | 40.0 |
Complement 4/analysis/*genetics | 6 | 75.0 |
Complement Factor B/analysis/*genetics | 2 | 33.0 |
HLA Antigens/genetics | 31 | 10.0 |
Hemolysis | 10 | 3.0 |
Genetics, Population | 3 | 0.0 |
Incidence | 2 | 0.0 |
Risk Factors | 14 | 0.0 |
Complement 4a/genetics | 11 | 57.0 |
Genes, MHC Class II/*genetics | 2 | 2.0 |
Severity of Illness Index | 3 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Pedigree | 51 | 0.0 |
Restriction Mapping | 10 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Immunogenetics | 4 | 8.0 |
Immunologic Techniques | 2 | 0.0 |
Linkage (Genetics) | 32 | 1.0 |
Complement/deficiency/*genetics | 2 | 100.0 |
Molecular Biology | 2 | 0.0 |
*Multigene Family | 4 | 0.0 |
Cardiolipins/*immunology | 2 | 16.0 |
Immunoglobulin A/immunology | 2 | 5.0 |
Immunoglobulin G/immunology | 4 | 1.0 |
Cell Line | 9 | 0.0 |
DNA/*genetics | 4 | 1.0 |
Peptide Fragments/*genetics | 2 | 4.0 |
*Homozygote | 4 | 2.0 |
*Phenotype | 2 | 0.0 |
Complement 2/*deficiency | 2 | 3.0 |
Haplotypes/*genetics | 2 | 1.0 |
Histocompatibility Antigens Class I/genetics | 3 | 3.0 |
Histocompatibility Antigens Class II/genetics | 16 | 13.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 7 | 14.0 |
Spain | 2 | 0.0 |
Complement Factor B/*genetics | 17 | 13.0 |
Italy | 9 | 1.0 |
Pregnancy | 6 | 0.0 |
*Genome, Human | 2 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Complement 4/metabolism | 5 | 5.0 |
Serotyping | 2 | 0.0 |
In Vitro | 8 | 0.0 |
HLA-DR4 Antigen/genetics/immunology | 2 | 50.0 |
Histocompatibility Testing | 15 | 1.0 |
Japan | 5 | 0.0 |
Complement/*genetics | 14 | 24.0 |
Complement Factor B/genetics | 17 | 24.0 |
*Haplotypes | 12 | 4.0 |
*Polymorphism, Restriction Fragment Length | 10 | 1.0 |
Complement 4b/immunology/*metabolism | 2 | 100.0 |
Protein Binding | 14 | 0.0 |
Radioligand Assay | 2 | 0.0 |
Complement 4b/*deficiency/genetics | 4 | 100.0 |
Binding Sites | 6 | 0.0 |
Receptors, Complement 3b/genetics/*metabolism | 2 | 100.0 |
Complement 4a/analysis/*genetics | 2 | 100.0 |
Complement Activation/*drug effects | 2 | 2.0 |
Complement Pathway, Classical/drug effects | 4 | 17.0 |
Complement 4/genetics | 20 | 32.0 |
Point Mutation | 2 | 0.0 |
China | 3 | 0.0 |
Proteins/*genetics | 4 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Complement/*metabolism | 3 | 1.0 |
Precipitin Tests | 4 | 0.0 |
Epitopes | 3 | 0.0 |
India | 4 | 1.0 |
Structure-Activity Relationship | 7 | 0.0 |
Arthritis, Rheumatoid/immunology | 4 | 4.0 |
Complement/*analysis/immunology | 2 | 22.0 |
Complement 4a/deficiency | 3 | 100.0 |
Complement Hemolytic Activity Assay | 2 | 4.0 |
Disease Progression | 2 | 0.0 |
Lupus Erythematosus, Systemic/*immunology | 3 | 2.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Autistic Disorder/*genetics/*immunology | 2 | 66.0 |
*Chromosomes, Human, Pair 6 | 4 | 1.0 |
Complement 4a/analysis | 3 | 42.0 |
Complement 4b/analysis | 2 | 50.0 |
HLA-DQ Antigens/analysis | 3 | 6.0 |
HLA-DR Antigens/analysis | 3 | 0.0 |
Wales | 2 | 11.0 |
Complement/analysis | 4 | 2.0 |
Prospective Studies | 4 | 0.0 |
Blood Coagulation Tests | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 9 | 0.0 |
Haplotypes/*immunology | 3 | 12.0 |
Korea | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Complement 4/genetics/*immunology | 7 | 100.0 |
Biopsy | 2 | 0.0 |
Complement 4/*deficiency/genetics | 13 | 81.0 |
HLA-DR Antigens/*genetics | 6 | 1.0 |
South Africa | 2 | 1.0 |
Densitometry | 3 | 2.0 |
Diabetes Mellitus, Type 1/immunology | 2 | 11.0 |
Immunophenotyping | 2 | 0.0 |
Complement 3/genetics | 4 | 11.0 |
HLA-B Antigens/genetics | 4 | 1.0 |
Disease Susceptibility | 9 | 1.0 |
Complement 2/*analysis/genetics | 2 | 100.0 |
Complement 4/*analysis/genetics | 3 | 75.0 |
HLA Antigens/analysis | 8 | 3.0 |
Isoelectric Focusing | 3 | 0.0 |
DNA | 4 | 0.0 |
*Introns | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Erythrocytes/immunology/*metabolism | 2 | 18.0 |
Opsonins | 2 | 4.0 |
*Adrenal Hyperplasia, Congenital | 3 | 13.0 |
Histocompatibility Antigens Class II/*genetics | 5 | 2.0 |
*Genes, Structural | 9 | 1.0 |
Organ Specificity | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 6 | 0.0 |
Complement 3b/immunology | 2 | 5.0 |
Complement 4b/immunology | 2 | 50.0 |
Complement 3b/metabolism | 2 | 1.0 |
Complement Factor B/*immunology | 2 | 33.0 |
Immunoglobulin Allotypes | 2 | 25.0 |
17-alpha-Hydroxyprogesterone | 2 | 4.0 |
Hydroxyprogesterones/blood | 2 | 4.0 |
Electrophoresis, Polyacrylamide Gel | 14 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Complement Activation | 7 | 2.0 |
Hemolytic Plaque Technique | 2 | 3.0 |
Cloning, Molecular | 6 | 0.0 |
Major Histocompatibility Complex/*immunology | 2 | 5.0 |
Complement 5/metabolism | 3 | 6.0 |
*Hemolysis | 3 | 3.0 |
Blood Group Antigens/*genetics | 5 | 4.0 |
Blood Grouping and Crossmatching/*methods | 2 | 7.0 |
Family Health | 4 | 0.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Complement 4/*deficiency/*genetics | 4 | 100.0 |
Complement 4/analysis/*deficiency/genetics | 2 | 100.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Binding Sites, Antibody | 2 | 0.0 |
Guinea Pigs | 9 | 1.0 |
Infant, Newborn | 8 | 0.0 |
Multigene Family | 8 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Age Factors | 6 | 0.0 |
Autoimmunity | 2 | 1.0 |
Chromosomes, Human, Pair 6 | 5 | 3.0 |
Complement 4b/*analysis/genetics | 2 | 100.0 |
HLA-DR Antigens | 15 | 4.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Complement 2/*genetics | 5 | 10.0 |
Gene Frequency/genetics | 3 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
Predictive Value of Tests | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Solubility | 4 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Complement 3b/*immunology | 2 | 8.0 |
*Complement Activation | 9 | 2.0 |
Lupus Erythematosus, Systemic/immunology | 2 | 1.0 |
Adrenal Hyperplasia, Congenital/enzymology/*genetics | 2 | 28.0 |
*Genes, MHC Class I | 4 | 1.0 |
*Genes, MHC Class II | 5 | 1.0 |
Pseudogenes | 3 | 1.0 |
Complement 4a/metabolism | 3 | 60.0 |
Glycerol/metabolism | 3 | 7.0 |
Glycine/metabolism | 3 | 13.0 |
Hydrolysis | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
*Adrenal Hyperplasia, Congenital/*genetics | 3 | 42.0 |
Chromosome Deletion | 18 | 2.0 |
Autoimmune Diseases/*genetics | 3 | 7.0 |
Electrophoresis | 4 | 1.0 |
Gene Amplification | 2 | 0.0 |
Immunologic Deficiency Syndromes/*genetics | 2 | 6.0 |
Immunodiffusion | 4 | 1.0 |
Prognosis | 5 | 0.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Immunoassay | 2 | 0.0 |
Complement 1s/metabolism | 2 | 16.0 |
Graves' Disease/*genetics/immunology | 2 | 18.0 |
Complement 4/*metabolism | 4 | 9.0 |
Complement 4b/metabolism | 2 | 8.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Receptors, Complement/*metabolism | 2 | 1.0 |
Adrenal Hyperplasia, Congenital/*genetics | 6 | 26.0 |
*Chromosome Deletion | 8 | 1.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
*Chromosome Mapping | 4 | 0.0 |
European Continental Ancestry Group | 9 | 1.0 |
*IgA Deficiency | 3 | 16.0 |
Complement Pathway, Alternative | 2 | 1.0 |
Haemophilus influenzae/*immunology | 2 | 8.0 |
Buffers | 2 | 1.0 |
Complement 4b/physiology | 2 | 66.0 |
Dose-Response Relationship, Immunologic | 4 | 0.0 |
Complement Pathway, Classical/*genetics | 2 | 40.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Hemolysis/genetics | 2 | 33.0 |
Plasmids | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Chickens | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
HLA-D Antigens/genetics | 2 | 5.0 |
San Francisco/epidemiology | 2 | 9.0 |
Sex Factors | 4 | 0.0 |
Tunisia | 2 | 4.0 |
Evolution | 4 | 1.0 |
Gorilla gorilla/*genetics | 2 | 25.0 |
Pongo pygmaeus/*genetics | 2 | 50.0 |
Complement 7/*deficiency/genetics | 2 | 16.0 |
Disease Models, Animal | 2 | 0.0 |
HLA Antigens/genetics/*immunology | 3 | 4.0 |
Haplotypes/genetics/*immunology | 2 | 100.0 |
Arthritis, Rheumatoid/genetics/*immunology | 2 | 5.0 |
Risk | 4 | 0.0 |
Abortion, Habitual/*genetics | 2 | 9.0 |
Blood Donors | 2 | 0.0 |
Complement 4/analysis | 3 | 1.0 |
Complement 4b/analysis/*genetics | 2 | 100.0 |
Immunoglobulin G/*analysis | 2 | 2.0 |
Penicillamine/*adverse effects/therapeutic use | 2 | 28.0 |
Pan troglodytes/*genetics | 2 | 7.0 |
Polymorphism, Genetic/immunology | 2 | 8.0 |
Antigen-Antibody Complex/*immunology | 3 | 3.0 |
Erythrocytes/metabolism | 2 | 1.0 |
*Precipitin Tests | 2 | 28.0 |
Antibodies/metabolism | 2 | 2.0 |
Complement 3 Convertase/metabolism | 3 | 7.0 |
Complement 2/deficiency/genetics | 2 | 40.0 |
Complement 4a/*deficiency/genetics | 2 | 50.0 |
Complement 4/*deficiency | 3 | 33.0 |
*Complement Inactivators | 4 | 5.0 |
*Glycoproteins | 3 | 0.0 |
Rabbits | 3 | 0.0 |
Complement 4/*analysis | 3 | 6.0 |
Erythrocytes/*immunology | 3 | 1.0 |
HLA-D Antigens/*analysis | 2 | 3.0 |
HLA-DR4 Antigen/analysis | 2 | 11.0 |
*Complement Pathway, Classical | 3 | 3.0 |
HLA-D Antigens/*genetics | 5 | 3.0 |
Immunoblotting | 3 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Histocompatibility Antigens Class II/analysis | 3 | 1.0 |
DNA Probes | 5 | 0.0 |
Complement 5/antagonists & inhibitors | 2 | 28.0 |
Monocytes/*immunology | 2 | 0.0 |
Receptors, Complement 3b | 5 | 1.0 |
*African Continental Ancestry Group | 4 | 3.0 |
Complement 4a/analysis/genetics | 2 | 100.0 |
United States | 3 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Macromolecular Substances | 6 | 0.0 |
Protein S | 2 | 3.0 |
Arthritis, Rheumatoid/*genetics/immunology | 3 | 6.0 |
Felty's Syndrome/*genetics | 2 | 66.0 |
Linkage Disequilibrium/genetics | 2 | 1.0 |
*Pseudogenes | 3 | 2.0 |
Complement/*deficiency | 2 | 4.0 |
Meningococcal Infections/*immunology | 2 | 25.0 |
Complement 3d | 2 | 2.0 |
Nucleic Acid Hybridization | 8 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
England | 2 | 1.0 |
Lupus Erythematosus, Systemic/ethnology/*genetics | 3 | 30.0 |
African Continental Ancestry Group | 2 | 0.0 |
Complement 4/analysis/deficiency/*genetics | 2 | 66.0 |
Glomerulonephritis, IGA/genetics/*immunology | 3 | 37.0 |
Complement Factor H | 2 | 2.0 |
Complement Factor I | 3 | 14.0 |
Sheep | 4 | 0.0 |
Complement 4/*genetics/immunology | 8 | 66.0 |
HLA Antigens | 2 | 1.0 |
Steroid Hydroxylases/*genetics | 12 | 13.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 3 | 5.0 |
Epitopes/genetics/immunology | 3 | 8.0 |
Chromatography, Affinity | 2 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Complement 4/isolation & purification/*metabolism | 2 | 66.0 |
Genes, MHC Class II | 8 | 3.0 |
HLA Antigens/*analysis/genetics | 2 | 2.0 |
Antibodies, Monoclonal/diagnostic use | 5 | 0.0 |
*Genes | 5 | 2.0 |
Epitopes/analysis | 2 | 0.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Immunoglobulin A/genetics | 2 | 20.0 |
Complement 4b | 50 | 53.0 |
HLA-B8 Antigen | 3 | 11.0 |
HLA-DR3 Antigen | 8 | 20.0 |
DNA Restriction Enzymes | 8 | 2.0 |
Hybridization, Genetic | 2 | 3.0 |
Arthritis, Rheumatoid/*genetics | 3 | 4.0 |
Complement 4a | 39 | 66.0 |
HLA-DR4 Antigen | 4 | 6.0 |
Complement Fixation Tests | 2 | 2.0 |
Molecular Weight | 10 | 0.0 |
Steroid Hydroxylases/*deficiency | 2 | 7.0 |
Antigen-Antibody Complex | 2 | 1.0 |
Complement 4/*genetics/physiology | 2 | 100.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
HLA Antigens/analysis/genetics | 3 | 11.0 |
Psoriasis/*genetics | 2 | 3.0 |
Enzyme Precursors/*genetics | 7 | 6.0 |
Lupus Erythematosus, Systemic/chemically induced | 3 | 100.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Lupus Erythematosus, Systemic/genetics/*immunology | 2 | 6.0 |
Lupus Erythematosus, Systemic/*genetics | 2 | 3.0 |
Blood Group Antigens/genetics | 2 | 3.0 |
Glycosylation | 2 | 0.0 |
HLA Antigens/*analysis | 3 | 0.0 |
Chemistry | 5 | 2.0 |
Complement 4b/deficiency/genetics | 2 | 100.0 |
Isoantibodies/biosynthesis | 2 | 20.0 |
*Complement 4b | 3 | 9.0 |
Peptide Fragments/immunology | 2 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Trypsin | 3 | 1.0 |
China/ethnology | 2 | 1.0 |
DNA Restriction Enzymes/diagnostic use | 2 | 5.0 |
Japan/ethnology | 2 | 2.0 |
Genes, Structural | 7 | 0.0 |
*HLA-B Antigens | 2 | 3.0 |
DNA, Recombinant/analysis | 2 | 10.0 |
Liver Neoplasms | 3 | 1.0 |
Epitopes/*analysis | 2 | 1.0 |
Hemagglutination Inhibition Tests | 2 | 4.0 |
Lactoylglutathione Lyase/genetics | 4 | 9.0 |
Finland | 2 | 0.0 |
Catalysis | 2 | 0.0 |
Complement 3 Convertase/biosynthesis | 2 | 22.0 |
Germany/ethnology | 2 | 15.0 |
Haploidy | 5 | 4.0 |
Multiple Sclerosis/genetics | 2 | 25.0 |
Immunosorbent Techniques | 2 | 0.0 |
Immunoelectrophoresis | 4 | 1.0 |
*Chromosomes, Human, 6-12 and X | 4 | 2.0 |
Recombination, Genetic | 3 | 0.0 |
Acylation | 2 | 2.0 |
HLA-B Antigens | 9 | 2.0 |
Complement 3 Convertase/*metabolism | 3 | 17.0 |
Complement Activating Enzymes/*metabolism | 3 | 9.0 |
Complement Factor B/metabolism | 2 | 4.0 |
Precipitation | 2 | 1.0 |
Diabetes Mellitus, Type 1/*genetics | 3 | 1.0 |
HLA Antigens/*genetics/immunology | 2 | 4.0 |
Histocompatibility Antigens Class II/*analysis | 2 | 1.0 |
*Complement 3 | 2 | 6.0 |
Peptide Fragments/isolation & purification | 3 | 5.0 |
Integrin alphaXbeta2 | 2 | 5.0 |
Half-Life | 2 | 0.0 |
Chromosomes, Human, 6-12 and X | 4 | 9.0 |
Swine | 2 | 0.0 |
Receptors, Complement/*physiology | 3 | 5.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 3 | 6.0 |
HLA-C Antigens | 2 | 1.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
Crossing Over, Genetic | 2 | 2.0 |
Rosette Formation | 3 | 0.0 |
*Complement 3 Convertase | 2 | 66.0 |
*Complement Activating Enzymes | 2 | 50.0 |
